Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 7/2011

Open Access 01-07-2011 | Original Article

Dopaminergic drugs and the risk of hip or femur fracture: a population-based case–control study

Authors: M. E. L. Arbouw, K. L. L. Movig, T. P. van Staa, A. C. G. Egberts, P. C. Souverein, F. de Vries

Published in: Osteoporosis International | Issue 7/2011

Login to get access

Abstract

Summary

The effect of dopaminergic medication on the risk of hip/femur fractures is not clear. Our results showed a nearly twofold increased risk of hip/femur fractures in current dopaminergic drug users. Concomitant use of antidepressants further increased this risk. Fracture risk assessment may be warranted in elderly users of dopaminergic drugs.

Introduction

Dopaminergic drugs, often used in the treatment of Parkinson’s disease, have several pharmacological effects that may increase or decrease the risk of falling and fractures. Thus, the effect of dopaminergic medication on the risk of hip/femur fractures is not clear. The objective of the study was to examine the effect of dopaminergic medication and concomitant use of psychotropics on the risk of hip/femur fractures taking into account the timing of dopaminergic drug use.

Methods

A population-based case–control study in the PHARMO database was conducted for the period 1991 to 2002. Cases were patients aged 18 years and older with a first hip or femur fracture and matched to four control patients by year of birth, sex and geographical region.

Results

The study population included 6,763 cases and 26,341 controls. Current use of dopaminergic drugs (1–30 days before the index date) was associated with an increased risk of hip/femur fractures compared to never use (ORadj 1.76, 95% CI = 1.39–2.22), but this excess risk rapidly dropped to baseline levels when treatment had been discontinued >1 year ago. Concomitant use of antidepressants among current dopaminergic drug users further increased the risk of hip/femur fractures (ORadj 3.51, 95% CI = 2.10–5.87) while there was no additional risk with concomitant use of other psychotropics.

Conclusions

Although the observed association between dopaminergic drugs and fracture risk may not be entirely causal, due to absence of information on the (severity of the) underlying disease, fracture risk assessment may be warranted in elderly users of dopaminergic drugs.
Literature
1.
Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442PubMed
2.
3.
Genever RW, Downes TW, Medcalf P (2005) Fracture rates in Parkinson’s disease compared with age- and gender-matched controls: a retrospective cohort study. Age Ageing 34:21–24PubMedCrossRef
4.
Johnell O, Melton LJ III, Atkinson EJ, O’Fallon WM, Kurland LT (1992) Fracture risk in patients with parkinsonism: a population-based study in Olmsted County, Minnesota. Age Ageing 21:32–38PubMedCrossRef
5.
Fink HA, Kuskowski MA, Taylor BC, Schousboe JT, Orwoll ES, Ensrud KE (2008) Association of Parkinson’s disease with accelerated bone loss, fractures and mortality in older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos Int 19:1277–1282PubMedCrossRef
6.
Schneider JL, Fink HA, Ewing SK, Ensrud KE, Cummings SR (2008) The association of Parkinson’s disease with bone mineral density and fracture in older women. Osteoporos Int 19:1093–1097PubMedCrossRef
7.
Koller WC, Glatt S, Vetere-Overfield B, Hassanein R (1989) Falls and Parkinson’s disease. Clin Neuropharmacol 12:98–105PubMedCrossRef
8.
Kamide N, Fukuda M, Miura H (2008) The relationship between bone density and the physical performance of ambulatory patients with Parkinson’s disease. J Physiol Anthropol 27:7–10PubMedCrossRef
9.
Sato Y, Kaji M, Tsuru T, Oizumi K (2001) Risk factors for hip fracture among elderly patients with Parkinson’s disease. J Neurol Sci 182:89–93PubMedCrossRef
10.
Bezza A, Ouzzif Z, Naji H, Achemlal L, Mounach A, Nouijai M, Bourazza A, Mossadeq R, El MA (2008) Prevalence and risk factors of osteoporosis in patients with Parkinson’s disease. Rheumatol Int 28:1205–1209PubMedCrossRef
11.
Bachmann CG, Trenkwalder C (2006) Body weight in patients with Parkinson’s disease. Mov Disord 21:1824–1830PubMedCrossRef
12.
Woodford H, Walker R (2005) Emergency hospital admissions in idiopathic Parkinson’s disease. Mov Disord 20:1104–1108PubMedCrossRef
13.
van Dijk JG, Haan J, Zwinderman K, Kremer B, van Hilten BJ, Roos RA (1993) Autonomic nervous system dysfunction in Parkinson’s disease: relationships with age, medication, duration, and severity. J Neurol Neurosurg Psychiatry 56:1090–1095PubMedCrossRef
14.
Homann CN, Wenzel K, Suppan K, Ivanic G, Kriechbaum N, Crevenna R, Ott E (2002) Sleep attacks in patients taking dopamine agonists: review. BMJ 324:1483–1487PubMedCrossRef
15.
Kaynak D, Kiziltan G, Kaynak H, Benbir G, Uysal O (2005) Sleep and sleepiness in patients with Parkinson’s disease before and after dopaminergic treatment. Eur J Neurol 12:199–207PubMedCrossRef
16.
Sato Y, Iwamoto J, Kanoko T, Satoh K (2005) Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson’s disease. Am J Med 118:1250–1255PubMedCrossRef
17.
Vestergaard P, Rejnmark L, Mosekilde L (2007) Fracture risk associated with parkinsonism and anti-Parkinson drugs. Calcif Tissue Int 81:153–161PubMedCrossRef
18.
Naliato EC, Violante AH, Caldas D, Farias ML, Bussade I, Lamounier FA, Loureiro CR, Fontes R, Schrank Y, Loures T, Colao A (2008) Bone density in women with prolactinoma treated with dopamine agonists. Pituitary 11:21–28PubMedCrossRef
19.
20.
Brandt-Christensen M, Garcia LA, Morkeberg NF, Kragh AP, Vedel KL (2007) Parkinson’s disease and antidepressant drug treatment: a case-register study. Parkinsonism Relat Disord 13:406–410PubMedCrossRef
21.
Vestergaard P, Rejnmark L, Mosekilde L (2008) Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif Tissue Int 82:92–101PubMedCrossRef
22.
Whooley MA, Kip KE, Cauley JA, Ensrud KE, Nevitt MC, Browner WS (1999) Depression, falls, and risk of fracture in older women. Study of Osteoporotic Fractures Research Group. Arch Intern Med 159:484–490PubMedCrossRef
23.
van den Brand MW, Samson MM, Pouwels S, van Staa TP, Thio B, Cooper C, Leufkens HG, Egberts AC, Verhaar HJ, De Vries F (2009) Use of anti-depressants and the risk of fracture of the hip or femur. Osteoporos Int 20:1705–1713PubMedCrossRef
24.
Marras C, Kopp A, Qiu F, Lang AE, Sykora K, Shulman KI, Rochon PA (2007) Antipsychotic use in older adults with Parkinson’s disease. Mov Disord 22:319–323PubMedCrossRef
25.
Hugenholtz GW, Heerdink ER, van Staa TP, Nolen WA, Egberts AC (2005) Risk of hip/femur fractures in patients using antipsychotics. Bone 37:864–870PubMedCrossRef
26.
Pouwels S, van Staa TP, Egberts AC, Leufkens HG, Cooper C, De Vries F (2009) Antipsychotic use and the risk of hip/femur fracture: a population-based case–control study. Osteoporos Int 20:1499–1506PubMedCrossRef
27.
Herings RM, Stricker BH, de Boer A, Bakker A, Sturmans F, Stergachis A (1996) Current use of thiazide diuretics and prevention of femur fractures. J Clin Epidemiol 49:115–119PubMedCrossRef
28.
Herings RM, Stricker BH, de Boer A, Bakker A, Sturmans F (1995) Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med 155:1801–1807PubMedCrossRef
29.
Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM (1995) Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332:767–773PubMedCrossRef
30.
van Staa TP, Geusens P, Kanis JA, Leufkens HG, Gehlbach S, Cooper C (2006) A simple clinical score for estimating the long-term risk of fracture in post-menopausal women. QJM 99:673–682PubMedCrossRef
31.
Greenland S (1995) Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 6:356–365PubMedCrossRef
32.
De Vries F, Souverein PC, Cooper C, Leufkens HG, van Staa TP (2007) Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands. Calcif Tissue Int 80:69–75PubMedCrossRef
33.
De Vries F, Pouwels S, Lammers JW, Leufkens HG, Bracke M, Cooper C, van Staa TP (2007) Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case–control study. J Intern Med 261:170–177PubMed
34.
35.
Thapa PB, Gideon P, Cost TW, Milam AB, Ray WA (1998) Antidepressants and the risk of falls among nursing home residents. N Engl J Med 339:875–882PubMedCrossRef
36.
Vestergaard P, Rejnmark L, Mosekilde L (2006) Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int 17:807–816PubMedCrossRef
37.
Meaney AM, Smith S, Howes OD, O’Brien M, Murray RM, O'Keane V (2004) Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 184:503–508PubMedCrossRef
38.
Van de Vijver DA, Stricker BH, Breteler MM, Roos RA, Porsius AJ, de Boer A (2001) Evaluation of antiparkinsonian drugs in pharmacy records as a marker for Parkinson's disease. Pharm World Sci 23:148–152PubMedCrossRef
39.
Lorefalt B, Toss G, Granerus AK (2007) Bone mass in elderly patients with Parkinson's disease. Acta Neurol Scand 116:248–254PubMedCrossRef
40.
Cauley JA, Fullman RL, Stone KL, Zmuda JM, Bauer DC, Barrett-Connor E, Ensrud K, Lau EM, Orwoll ES (2005) Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int 16:1525–1537PubMedCrossRef
41.
Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, Fujiwara S, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16:155–162PubMedCrossRef
42.
Powers KM, Kay DM, Factor SA, Zabetian CP, Higgins DS, Samii A, Nutt JG, Griffith A, Leis B, Roberts JW, Martinez ED, Montimurro JS, Checkoway H, Payami H (2008) Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Mov Disord 23:88–95PubMedCrossRef
Metadata
Title
Dopaminergic drugs and the risk of hip or femur fracture: a population-based case–control study
Authors
M. E. L. Arbouw
K. L. L. Movig
T. P. van Staa
A. C. G. Egberts
P. C. Souverein
F. de Vries
Publication date
01-07-2011
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 7/2011
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-010-1455-3

Other articles of this Issue 7/2011

Osteoporosis International 7/2011 Go to the issue

Original Article

The relationship of fetuin-A and lactoferrin with bone mass in elderly women

Original Article

Implementation of osteoporosis guidelines: a survey of five large fracture liaison services in the Netherlands

Original Article

Bone mass in male and female children and adolescents with Down syndrome

Original Article

C-reactive protein predicts incident fracture in community-dwelling elderly Japanese women: the Muramatsu study

Letter

Atypical femoral stress fractures in bisphosphonate-free patients

Review

Systematic review on interventions to improve osteoporosis investigation and treatment in fragility fracture patients